^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
IBI-130
i
Other names: IBI-130, IBI130
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Innovent Biologics
Drug class:
Topoisomerase I inhibitor, TROP-2-targeted antibody-drug conjugate
Related drugs:
over1year
A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1/2, N=182, Recruiting, Innovent Biologics (Suzhou) Co. Ltd. | Not yet recruiting --> Recruiting
Enrollment open
|
IBI-130
2years
A Phase 1/2 Clinical Study to Evaluate the Safety and Tolerability of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
P1/2, N=182, Not yet recruiting, Innovent Biologics (Suzhou) Co. Ltd.
New P1/2 trial • Metastases
|
IBI-130
Share via
